Yılmaz, AhmetHanlıoğlu, SelinDemiral, GökhanKaratepe, Oğuzhan2023-12-112023-12-112023Yılmaz, A., Hanlıoğlu, S., Demiral, G. ve Karatepe, O. (2023). The efficacy of liraglutide combined with intragastric balloon on weight loss. Revista da Associacao Medica Brasileira, 69(12). https://dx.doi.org/10.1590/1806-9282.202305710104-42301806-9282https://dx.doi.org/10.1590/1806-9282.20230571https://hdl.handle.net/20.500.12511/11976OBJECTIVE: Intragastric balloon placement is an effective method for weight reduction. The aim of this study was to evaluate the efficacy of combining liraglutide with intragastric balloon.METHODS: Initially, demographic data of patients such as age, gender, comorbid diseases, adverse events, initial weight, height, body mass index,percent body fat, and waist-hip ratio were collected. Weight, body mass index, percent body fat, and waist-hip ratio were measured in the second, third, fourth, fifth, and sixth months. Then, intragastric balloon was removed and liraglutide was stopped.RESULTS: A total of 50 patients were included in the study, of whom 28 (56%) were in Group A (intragastric balloon) and 22 (44%) were in Group B (plus liraglutide). Weight change at the time of balloon removal was higher in Group B [median weight change 13.8 (7.8 min to 16.8 max) versus 7.9 (4.8 min to 11.8 max); p<0.01]. When the weight, percent body fat, body mass index, and waist-hip ratio changes were compared according to gender, no significant difference was observed in the groups. Comorbid diseases were hypertension in 7 patients (4 in Group A and 3 in Group B) and diabetes in 9 patients (5 in Group A and 4 in Group B). No statistical significance was found.CONCLUSION: Liraglutide has benefits in terms of weight, percent body fat, and body mass index reduction when administered with intragastric balloon.eninfo:eu-repo/semantics/openAccessGlucagon-Like Peptide 1Gastric BalloonLiraglutideObesityBody Weight ChangesArticle691210.1590/1806-9282.20230571Q40011073215000012-s2.0-8517799196037971120Q3